Muhammad Naeem Azhar, Muhammad Ali Haider, Haroon Tayyab, Arslan Ahmed, Zaheerud Din Aqil Qazi.
Intravitreal bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age related macular degeneration.
Pak J Ophthalmol Jan ;28(4):211-3.

Purpose: To determine the mean percentage decrease in central macular thickness with intravitreal Bevacizumab for the treatment of subfoveal Choroidal Neovascularization secondary to Age related Macular Degeneration. Material and Methods: From September 2009 to March 2010, thirty five diagnosed patients of subfoveal choroidal neovascularization secondary to age related macular degeneration were taken from out-door patient department of Layton Rahmatulla Benevolent Trust Eye and Cancer Hospital, Lahore. After taking aseptic measures intravitreal Bevacizumab (Avastin) injection (1.25 mg/ 0.05 ml) was injected through pars plana. Post injections follow up was done by central macular thickness (in µm) measured by Optical coherence tomography at 4 th week, 8th week and finally at 12th week. Results: Thirty five eyes of 35 consecutive patients received the three injections of intravitreal Bevacizumab 1.25 mg / 0.05 ml, each injection 4 weeks apart and all patients had 3 months of follow up. Mean central macular thickness ± SD decreased from 308.86 ± 39.13 µm at baseline to 228 ± 17.62 µm at 12th week. In our study mean percentage decrease in central macular thickness was 26.18% at 12th week after three intravitreal Bevacizumab injections. Conclusion: Intravitreal Bevacizumab injection results in short term decrease in central macular thickness to normal or near-normal levels in eyes with choroidal neovascularization secondary to age-related macular degeneration.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com